Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Valderm ApS

Home Clinical Trial Sponsors and OrganizationsValderm ApS

Valderm ApS

CLOSED

Denmarkwww.valderm.dkPrivateEstablished: 2003-01-01

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

3

3 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

2003

Overview

Trial Phase Distribution

No trial phase data available

Trial Status Distribution

Active, not recruiting

3

100.0%

Clinical Trials

Trials sponsored by this organization (3)

A phase IIa, multicenter, randomized, two-arm, observer-blind, vehicle and reference controlled proof of concept trial to investigate intra-individually (left/ right) the antipsoriatic efficacy and safety of once daily topical application of Valrubicin cream 1 % in comparison to vehicle and reference product in adult patients with stable plaque psoriasis

Active, not recruiting

Dec 201046 participants

A phase IIa, single-center, randomized, observer-blind, placebo- and reference-controlled proof of concept study with intraindividual comparison of treatments to investigate the safety and antipsoriatic efficacy of topical valrubicin formulations in a psoriasis plaque test - Efficacy and tolerability of varubicin cream in concentrations of 0.5 % and 1 % in a PPT

Active, not recruiting

A 13 day placebo- and reference-controlled, double-blind, monocentric, randomized, intraindividual comparative clinical phase IIa study, investigating the efficacy and tolerability of valrubicin cream 0.01 %, 0.1 % and 1 % in a panel of 24 patients with Psoriasis in a Psoriasis plaque test

Active, not recruiting

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials3
Approvals
News

Back to Organizations